Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917440 | 0.91 | HDAC6 (0.47) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL16418008 | 0.89 | RAB9A (0.44) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917429 | 0.84 | RAB9A (0.41) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917423 | 0.81 | RAB9A (0.41) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917431 | 0.79 | LMNA (0.49) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917425 | 0.78 | LMNA (0.48) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917422 | 0.78 | HDAC6 (0.54) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917442 | 0.77 | HDAC6 (0.48) | RAB9ANPC1KMT2AMEN1HDAC6 | |
| SCHEMBL16772292 | 0.77 | SMN1; SMN2 (0.45) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL9917441 | 0.74 | HDAC6 (0.48) | RAB9ANPC1KMT2AMEN1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-06-04 | — | — | US | disclosed |
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | RAB9A 2617/4885SMN1; SMN2 2247/4885DUSP3 358/4885 |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | RAB9A 2617/4885SMN1; SMN2 2247/4885DUSP3 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.